FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947633439> ?p ?o ?g. }

• W2947633439 endingPage "5518" @default.
• W2947633439 startingPage "5518" @default.
• W2947633439 abstract "5518 Background: Platinum resistant ovarian cancer (OC) remains a therapeutic challenge. High grade serous OC (HGSOC) harbors TP53 mutations leading to increased dependency on S- and G2-phase checkpoints. Wee1 inhibition with Adavosertib (AZD 1775) (A) induces G2 checkpoint escape. Gemcitabine (G) is an antimetabolite therapy and blocks the progression of cells through the G1/S phase. We hypothesized that combining G+A would be synergistic and overcome resistance. Methods: We conducted a multicentre double-blind 2:1 randomized phase 2 trial to assess the progression free survival (PFS) in women with recurrent platinum-resistant/refractory HGSOC receiving G+A or G+placebo (P) (NCT02151292). Eligibility required measurable disease and feasibility of paired tumor biopsies; no limitation in prior lines of therapy. Non HGSOC histologic subtypes were enrolled in a separate non-randomized exploratory cohort. A/P was given orally at 175mg QD on D1-2, D8-9 and D15-16 with G 1000mg/m² IV D1, D8 and D15 in a 28-day cycle until progression or unacceptable AE. Tumor staging was scheduled every 8 weeks. TP53 mutations were analyzed on archival tissue with Sanger sequencing, TAm-Seq and IHC. TP53 mutation will be also assessed in circulating tumor DNA (ctDNA). Whole exome and RNA sequencing were performed on paired tumor tissues. Results: 124 patients (pts) with median of 3 prior lines of therapy (range 1-10) from 12 centres across Canada and US were enrolled between Sep 2014 to May 2018, with 99 pts randomized (65 in Arm G+A and 34 in G+P). 5 pts were ineligible; 64 pts have died. The median follow-up was 14.3 months. Main related AE was hematologic toxicity (Anemia G≥3: 31% in G+A vs 18% in G+P; Thrombocytopenia G≥3: 31% vs 6%; Neutropenia G≥3: 62% vs 30%). PFS was significantly improved from 3.0 to 4.6 months (HR 0.56 (95%CI: 0.35-0.90, p=0.015 Log rank). There was a significant improvement in overall survival (OS) from 7.2 to 11.5 months (HR 0.56 (95%CI: 0.34-0.92, P=0.022). Partial response by RECIST 1.1 was observed in 13 (21%) and 1 (3%) pts for Arms G+A and G+P, respectively (p=0.02). From the 25 pts in the exploratory cohort, 3 (12%) partial responses were observed. Final results will be reported at the meeting. Conclusion: Addition of adavosertib to gemcitabine in women with platinum resistant/refractory OC improved response rate, PFS and OS with manageable toxicity. Clinical trial information: NCT02151292." @default.
• W2947633439 created "2019-06-07" @default.
• W2947633439 creator A5009546869 @default.
• W2947633439 creator A5011411233 @default.
• W2947633439 creator A5014979440 @default.
• W2947633439 creator A5016505594 @default.
• W2947633439 creator A5019722619 @default.
• W2947633439 creator A5023284324 @default.
• W2947633439 creator A5028677586 @default.
• W2947633439 creator A5030655014 @default.
• W2947633439 creator A5036689689 @default.
• W2947633439 creator A5042137756 @default.
• W2947633439 creator A5042269391 @default.
• W2947633439 creator A5046031005 @default.
• W2947633439 creator A5046159625 @default.
• W2947633439 creator A5051505642 @default.
• W2947633439 creator A5051525398 @default.
• W2947633439 creator A5059711716 @default.
• W2947633439 creator A5060761028 @default.
• W2947633439 creator A5068173453 @default.
• W2947633439 creator A5072712459 @default.
• W2947633439 date "2019-05-20" @default.
• W2947633439 modified "2023-10-13" @default.
• W2947633439 title "A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia." @default.
• W2947633439 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.5518" @default.
• W2947633439 hasPublicationYear "2019" @default.
• W2947633439 type Work @default.
• W2947633439 sameAs 2947633439 @default.
• W2947633439 citedByCount "14" @default.
• W2947633439 countsByYear W29476334392019 @default.
• W2947633439 countsByYear W29476334392020 @default.
• W2947633439 countsByYear W29476334392021 @default.
• W2947633439 countsByYear W29476334392022 @default.
• W2947633439 countsByYear W29476334392023 @default.
• W2947633439 crossrefType "journal-article" @default.
• W2947633439 hasAuthorship W2947633439A5009546869 @default.
• W2947633439 hasAuthorship W2947633439A5011411233 @default.
• W2947633439 hasAuthorship W2947633439A5014979440 @default.
• W2947633439 hasAuthorship W2947633439A5016505594 @default.
• W2947633439 hasAuthorship W2947633439A5019722619 @default.
• W2947633439 hasAuthorship W2947633439A5023284324 @default.
• W2947633439 hasAuthorship W2947633439A5028677586 @default.
• W2947633439 hasAuthorship W2947633439A5030655014 @default.
• W2947633439 hasAuthorship W2947633439A5036689689 @default.
• W2947633439 hasAuthorship W2947633439A5042137756 @default.
• W2947633439 hasAuthorship W2947633439A5042269391 @default.
• W2947633439 hasAuthorship W2947633439A5046031005 @default.
• W2947633439 hasAuthorship W2947633439A5046159625 @default.
• W2947633439 hasAuthorship W2947633439A5051505642 @default.
• W2947633439 hasAuthorship W2947633439A5051525398 @default.
• W2947633439 hasAuthorship W2947633439A5059711716 @default.
• W2947633439 hasAuthorship W2947633439A5060761028 @default.
• W2947633439 hasAuthorship W2947633439A5068173453 @default.
• W2947633439 hasAuthorship W2947633439A5072712459 @default.
• W2947633439 hasConcept C104317684 @default.
• W2947633439 hasConcept C121608353 @default.
• W2947633439 hasConcept C126322002 @default.
• W2947633439 hasConcept C142724271 @default.
• W2947633439 hasConcept C143998085 @default.
• W2947633439 hasConcept C182979987 @default.
• W2947633439 hasConcept C185592680 @default.
• W2947633439 hasConcept C204787440 @default.
• W2947633439 hasConcept C27081682 @default.
• W2947633439 hasConcept C2776694085 @default.
• W2947633439 hasConcept C2779962180 @default.
• W2947633439 hasConcept C2780194787 @default.
• W2947633439 hasConcept C2780258809 @default.
• W2947633439 hasConcept C2780427987 @default.
• W2947633439 hasConcept C2780739268 @default.
• W2947633439 hasConcept C55493867 @default.
• W2947633439 hasConcept C71924100 @default.
• W2947633439 hasConcept C82381507 @default.
• W2947633439 hasConceptScore W2947633439C104317684 @default.
• W2947633439 hasConceptScore W2947633439C121608353 @default.
• W2947633439 hasConceptScore W2947633439C126322002 @default.
• W2947633439 hasConceptScore W2947633439C142724271 @default.
• W2947633439 hasConceptScore W2947633439C143998085 @default.
• W2947633439 hasConceptScore W2947633439C182979987 @default.
• W2947633439 hasConceptScore W2947633439C185592680 @default.
• W2947633439 hasConceptScore W2947633439C204787440 @default.
• W2947633439 hasConceptScore W2947633439C27081682 @default.
• W2947633439 hasConceptScore W2947633439C2776694085 @default.
• W2947633439 hasConceptScore W2947633439C2779962180 @default.
• W2947633439 hasConceptScore W2947633439C2780194787 @default.
• W2947633439 hasConceptScore W2947633439C2780258809 @default.
• W2947633439 hasConceptScore W2947633439C2780427987 @default.
• W2947633439 hasConceptScore W2947633439C2780739268 @default.
• W2947633439 hasConceptScore W2947633439C55493867 @default.
• W2947633439 hasConceptScore W2947633439C71924100 @default.
• W2947633439 hasConceptScore W2947633439C82381507 @default.
• W2947633439 hasIssue "15_suppl" @default.
• W2947633439 hasLocation W29476334391 @default.
• W2947633439 hasOpenAccess W2947633439 @default.
• W2947633439 hasPrimaryLocation W29476334391 @default.
• W2947633439 hasRelatedWork W1661254177 @default.
• W2947633439 hasRelatedWork W2089394671 @default.
• W2947633439 hasRelatedWork W2149430132 @default.
• W2947633439 hasRelatedWork W2531990663 @default.

• next